Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines

被引:111
|
作者
Bauer, Michael [1 ]
Severus, Emanuel [1 ]
Moller, Hans-Jurgen [2 ]
Young, Allan H. [3 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Psychiat & Psychotherapy, Fetscherstr 74, D-01307 Dresden, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Psychiat, Munich, Germany
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England
关键词
Primary care; major depressive disorder; pharmacotherapy; guidelines; CONTINUATION TREATMENT; BIOLOGICAL TREATMENT; CONTROLLED-TRIALS; MAJOR DEPRESSION; WORLD FEDERATION; DOUBLE-BLIND; ANTIDEPRESSANTS; METAANALYSIS; UPDATE; MANAGEMENT;
D O I
10.1080/13651501.2017.1306082
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Major depressive disorder (MDD) is a severe mood disorder affecting individuals of all ages and is characterised by single or recurrent major depressive episodes. Key elements of acute and maintenance treatment of MDD include pharmacotherapy, and psychological approaches such as psychoeducation and adherence monitoring.Methods: This summary of the Practice guidelines for the biological treatment of unipolar depressive disorders' comprises acute, continuation and maintenance treatment developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP), and focuses on pharmacological treatment options.Results: A variety of different antidepressants are available for the effective acute and prophylactic treatment of depressed patients. Randomised placebo-controlled efficacy studies indicate that all major classes of antidepressants are effective in acute treatment but also in preventing recurrence of depression showing about a two-fold higher relapse rate with placebo treatment. Evidence suggests that the newer' antidepressants have superior long-term effectiveness due to better tolerability and safety profile compared to traditional antidepressants, e.g., the tricyclic antidepressants (TCA).Conclusions: Despite progress in the availability of different treatment options there is still a substantial proportion of patients who do not achieve full remission. Several add-on pharmacological treatment options are among the best-evidenced strategies for refractory depressed patients.
引用
收藏
页码:166 / 176
页数:11
相关论文
共 50 条
  • [11] Commentary on guidelines for the pharmacological treatment of paraphilic disorders
    Krueger, Richard B.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2020, 21 (06) : 409 - 411
  • [12] Unipolar depressive disorders
    Moeller, H. -J.
    NERVENARZT, 2009, 80 (05): : 513 - 514
  • [13] Impact of pharmacological and psychological treatment methods of depressive and anxiety disorders on cognitive functioning
    Krysta, Krzysztof
    Krzystanek, Marek
    Janas-Kozik, Malgorzata
    Klasik, Adam
    Krupka-Matuszczyk, Irena
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 : 101 - 110
  • [14] Effect of Depressive Disorders and Their Pharmacological Treatment during Pregnancy on Maternal and Neonatal Outcome
    Parpinel, Giulia
    Rosso, Gianluca
    Galante, Arianna
    Germano, Chiara
    Aragno, Elena
    Girlando, Flavia
    Messina, Alessandro
    Laudani, Maria Elena
    Rolfo, Alessandro
    Attini, Rossella
    Revelli, Alberto
    Maina, Giuseppe
    Masturzo, Bianca
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
  • [15] WFSBP Treatment Guidelines and the problem of evidence grading
    Hans Jürgen Möller
    Annals of General Psychiatry, 9 (Suppl 1)
  • [16] Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-release Trazodone
    Di Nicola, Marco
    Pepe, Maria
    Panaccione, Isabella
    Moccia, Lorenzo
    Janiri, Luigi
    Sani, Gabriele
    CURRENT NEUROPHARMACOLOGY, 2023, 21 (11) : 2195 - 2205
  • [17] Neurocognitive profile of outpatients with unipolar depressive disorders
    Schwert, Christine
    Stohrer, Maren
    Aschenbrenner, Steffen
    Weisbrod, Matthias
    Schroeder, Annette
    JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 2019, 41 (09) : 913 - 924
  • [18] A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders
    Serretti, Alessandro
    Olgiati, Paolo
    Bajo, Emanuele
    Bigelli, Marco
    De Ronchi, Diana
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2011, 12 (07) : 501 - 515
  • [19] The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression
    Grunze, Heinz
    Vieta, Eduard
    Goodwin, Guy M.
    Bowden, Charles
    Licht, Rasmus W.
    Moeller, Hans-Juergen
    Kasper, Siegfried
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2010, 11 (02) : 81 - 109
  • [20] WFSBP guidelines on how to grade treatment evidence for clinical guideline development
    Hasan, Alkomiet
    Bandelow, Borwin
    Yatham, Lakshmi N.
    Berk, Michael
    Falkai, Peter
    Moeller, Hans-Juergen
    Kasper, Siegfried
    Bauer, Michael
    Bras, Marijana
    Courtet, Philippe
    Bras, Marijana
    Dubois, Bruno
    Eap, Chin B.
    Gaebel, Wolfgang
    Halaris, Angelos
    Kasper, Siegfried
    Kates, Nick
    Kaye, Walter
    Kennedy, Sidney
    Kranzler, Henry R.
    Lanzenberger, Rupert
    Lieberman, Jeffrey
    Paris, Joel
    Petrides, Georgios
    Rujescu, Dan
    Schlaepfer, Thomas
    Schmitt, Andrea
    Sher, Leo
    Soldatos, Constantin
    Stefanis, Nikos
    Thibaut, Florence
    Tolga, Tanelki
    Treasure, Janet
    Zohar, Josef
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2019, 20 (01) : 2 - 16